Brief: Oryzon Receives FDA Feedback On Submitted Phase III Protocol For Borderline Personality Disorder
17/10/2025 17:11
Oct 17 (Reuters) - Oryzon Genomics SA ORY.MC: ORYZON RECEIVES FEEDBACK FROM THE FDA IN RESPONSE TO THE SUBMITTED PHASE III PROTOCOL IN BORDERLINE PERSONALITY DISORDER ORYZON - FDA GUIDANCE INCLUDES STUDY ENDPOINTS AND NON-CLINICAL CONSIDERATIONS Source text: ID:nGNX2Q5ZTw Further company coverage: ORY.MC ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28